Almac Boosts Capacity and Productivity with Acquisition of New Encapsulation Equipment
News Mar 02, 2012
Almac has addressed a surge in clinical outsourcing by acquiring two new pieces of encapsulation equipment at their North American headquarters in Souderton, PA.
The Bosch GKF 702 capsule filler with integrated KKE 1700 checkweigher comes as a significant investment for the company close to the one year anniversary of the US headquarters’ grand opening.
The acquisition gives added value to the already impressive array of over-encapsulation capabilities offered by the global service provider as part of a complete clinical supply chain management portfolio.
The Bosch cGMP-compliant system is able to produce 42,000 capsules per hour compared to the 2,700-4,500 output of Almac’s current machine in the United States.
Further capabilities of the new equipment include powder, pellet, tablet, and placebo fill as well as multi-fill.
The addition now creates balance between Almac’s EU and US sites by providing the same capacity to handle large and smaller scale projects simultaneously.
“This level of investment in encapsulation technology allows us to expand our capacity within our core services and shows our commitment to our clients,” says Dan Megill, Director of Operations at Almac.
Megill continued, “Bosch was chosen by Almac because they are a leader in capsule filling and weighing equipment with a variety of options. We are extremely pleased with this acquisition and expect it to contribute greatly to Almac’s overall productivity.”
The KKE 1700 checkweighing machinery strengthens the acquisition by offering comprehensive documentation of the production batches, optimal pharmaceutical security, and a high degree of productivity.
The GKF 702 with its upgraded performance builds on the success of the previous GKF 701 model and the machine offers many advantages for research and development.
The machine’s modular design offers the possibility to retrofit any future filling needs and all new filling stations currently in development will be compatible with this machine type.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE